Philippe Nuss

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Major Depressive Disorder

Patient Reported Outcomes

Top Venues

Molecular psychiatry

Expert review of neurotherapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Guillaume Fond, Bruno Falissard, Philippe Nuss, Cedric Collin, Stephanie Duret, Marc Rabbani, Isabelle De Chefdebien, Isabelle Tonelli, Pierre Michel Llorca, Laurent Boyer
How can we improve the care of patients with schizophrenia in the real-world? A population-based cohort study of 456,003 patients. Molecular psychiatry (2023)
Rusina Hazarosova, Albena Momchilova, Victoria Vitkova, Vesela Yordanova, Aneliya Kostadinova, Miglena I Angelova, Cedric Tessier, Philippe Nuss, Galya Staneva
Structural Changes Induced by Resveratrol in Monounsaturated and Polyunsaturated Phosphatidylcholine-Enriched Model Membranes. Membranes 13 (12) (2023)
Laurent Boyer, Bruno Falissard, Philippe Nuss, Cedric Collin, Stephanie Duret, Marc Rabbani, Isabelle De Chefdebien, Isabelle Tonelli, Pierre Michel Llorca, Guillaume Fond
Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders. Molecular psychiatry (2023)
Rusina Hazarosova, Albena Momchilova, Victoria Vitkova, Vesela Yordanova, Aneliya Kostadinova, Miglena I Angelova, Cedric Tessier, Philippe Nuss, Galya Staneva
Structural Changes Induced by Resveratrol in Monounsaturated and Polyunsaturated Phosphatidylcholine-Enriched Model Membranes. Membranes 13 (12) (2023)
Rusina Hazarosova, Albena Momchilova, Victoria Vitkova, Vesela Yordanova, Aneliya Kostadinova, Miglena I Angelova, Cedric Tessier, Philippe Nuss, Galya Staneva
Structural Changes Induced by Resveratrol in Monounsaturated and Polyunsaturated Phosphatidylcholine-Enriched Model Membranes. Membranes 13 (12) (2023)
Philippe Nuss, Emmanuelle Corruble, Emmanuelle Baloche, Ricardo P Garay, Pierre Michel Llorca
Fifty years of experience with loxapine for the rapid non-coercive tranquilization of acute behavioral disturbances in schizophrenia patients, and beyond. Expert review of neurotherapeutics 22 (8) (2022)